Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Business Wire
Grew full-year revenue to between $515 million and $517 million, an increase of 16% SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Unaudited Financial ResultsFor the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:Total revenue of between $138 million and $140 million, an increase of between 16% and 18%Testing revenue of between $134 million and $136 million, an increase of between 19% and 21%Testing volume of approximately 45,500, an increase of 16%For the full year ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:Total revenue of between $515 million and $517 million, an increase of approximately 16%Testing revenue of between $491 million and $493 million, an increase of approximately
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte (NASDAQ:VCYT) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results [Yahoo! Finance]Yahoo! Finance
- Veracyte (NASDAQ:VCYT) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Veracyte (VCYT): Assessing Whether Recent Momentum Justifies Its Current Valuation [Yahoo! Finance]Yahoo! Finance
- Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
VCYT
Earnings
- 11/4/25 - Beat
VCYT
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- 12/17/25 - Form 4
- VCYT's page on the SEC website